Market research
II2Q.F InspireMD, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.99
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.99
About
About InspireMD, Inc
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the II2Q.F discussion.
5 years, 5 months ago
InspireMD, Inc is currently in a long term downtrend where the price is trading 4.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.8.
InspireMD, Inc's total revenue sank by 84.4% to $158K since the same quarter in the previous year.
Its net income has dropped by 50.7% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 39.5% to $-2M since the same quarter in the previous year.
Based on the above factors, InspireMD, Inc gets an overall score of 1/5.